Retatrutide research: the full Phase 1 through Phase 2 record, and what Phase 3 is designed to determine.

Where the evidence stands

Retatrutide research has cleared Phase 1b and two Phase 2 trials with published results — one in obesity, one in type 2 diabetes, plus a Phase 2a metabolic liver-disease sub-study. A structural pharmacology paper resolved the triple-receptor binding at near-atomic resolution. Phase 3 is active but unpublished as of mid-2026.

This compound is not an approved drug. The research record is real and the effect sizes are large by historical standards. That record ends at Phase 2. Phase 3 will determine whether those effects hold at scale and what the long-term outcomes look like. These two facts — large Phase 2 effect, no Phase 3 result yet — are the load-bearing structure of the Retatrutide research story.

Triple-receptor mechanism: how the structure was resolved

Retatrutide (LY3437943) is a 39-amino-acid synthetic peptide built on a GIP (glucose-dependent insulinotropic polypeptide) backbone, acylated with a C20 fatty-diacid chain for albumin binding and extended circulation time — the same engineering approach used in other long-acting incretin peptides ^[3].

Cryo-EM (cryo-electron microscopy — an imaging technique that visualizes protein structures frozen in solution at near-atomic resolution) structures published in Cell Discovery in 2024 confirmed that retatrutide engages all three receptor complexes: GLP-1R (glucagon-like peptide-1 receptor), GIPR (glucose-dependent insulinotropic polypeptide receptor), and GCGR (glucagon receptor). Resolution was 2.68/3.26/2.84 Angstroms across the three complexes ^[3].

Relative potency versus endogenous hormones: approximately 8.9x at GIPR (high selectivity), 0.4x at GLP-1R, and 0.3x at GCGR — a deliberate profile that trades off some individual receptor potency against the breadth of three simultaneous signals ^[3]. The extracellular loop 1 (ECL1) adopts distinct conformations at each receptor — a rigid alpha-helix at GLP-1R and GCGR, a flexible loop at GIPR — explaining how a single molecule achieves simultaneous engagement.

The net pharmacological effect: GLP-1R and GIPR activation suppresses appetite and amplifies glucose-dependent insulin secretion; GCGR activation increases energy expenditure and mobilizes hepatic lipids. The glucagon arm is the mechanistic addition that single- and dual-agonist compounds lack ^[6].

Phase 1b: pharmacokinetics and first-in-human weight data

The first-in-human Phase 1b trial (Urva et al., Lancet, 2022) enrolled 72 adults with type 2 diabetes and administered once-weekly subcutaneous injections at doses ranging from 0.5 mg up to 3/6/9/12 mg in a multiple-ascending-dose design over 12 weeks ^[4].

Key findings: retatrutide half-life approximately 6 days, supporting once-weekly dosing. Placebo-adjusted weight change at the highest dose: -8.96 kg (90% CI -11.16 to -6.75) over 12 weeks. Daily blood glucose lowered by -2.8 mmol/L at 3 mg. Treatment-emergent adverse events in 63% of participants, predominantly GI. Acceptable safety profile at doses studied ^[4].

Phase 2 obesity trial: the -24.2% endpoint

Jastreboff et al. (NEJM, 2023) enrolled 338 adults with obesity (BMI ≥30 or ≥27 with comorbidity; 51.8% men) in a 48-week randomized double-blind trial ^[1]. Doses: 1, 4, 8, and 12 mg subcutaneous once weekly, with dose escalation to manage tolerability.

Primary endpoint result: mean body-weight change at 48 weeks was -24.2% at 12 mg versus -2.1% with placebo. All active dose groups showed significant separation from placebo. GI adverse events — nausea, diarrhea, vomiting, constipation — were the most common adverse events, dose-related, and predominantly mild to moderate. Discontinuation rate at 12 mg: 18%, primarily GI-driven. Dose-dependent heart-rate increase: peaking around 24 weeks, then partially attenuating ^[1].

The -24.2% figure is the most-cited number in the retatrutide literature. It is a 48-week Phase 2 result in a selected population. A 2025 review characterized it as a step-change versus prior incretin therapies and the largest weight reduction achieved with pharmacotherapy in a randomized trial at the time of publication ^[6].

Phase 2 type 2 diabetes trial

Rosenstock et al. (Lancet, 2023) enrolled 281 adults with type 2 diabetes in a 36-week trial with dose escalation from 0.5 to 12 mg once weekly, including active comparator arms ^[2].

Results at 12 mg: HbA1c -2.02% at 24 weeks versus -0.01% placebo; body weight -16.94% at 36 weeks versus -3.00% placebo. Mild-to-moderate GI adverse events in 35% of participants. No severe hypoglycemia and no deaths. Participants on background insulin required insulin dose reductions during the trial — a signal that matters for combination-use safety ^[2].

MASLD substudy: liver fat clearance

Sanyal et al. (Nature Medicine, 2024) enrolled 98 participants with obesity or overweight and MASLD (≥10% liver fat by MRI-PDFF, no T2D) as a substudy of the Phase 2 obesity trial ^[5].

Liver-fat reduction at 24 weeks by MRI-PDFF (magnetic resonance imaging proton density fat fraction — a non-invasive measure of liver fat content): -42.9% / -57.0% / -81.4% / -82.4% at doses 1/4/8/12 mg versus +0.3% placebo. Normal liver fat (below 5%) achieved in 86% of participants at 12 mg. Reductions sustained to 48 weeks at -86.0% ^[5].

Retatrutide vs tirzepatide

Direct head-to-head data between retatrutide and tirzepatide (a dual GIP/GLP-1 agonist) does not yet exist in the published literature. NCT06662383 is a Phase 3 active-comparator trial designed specifically to compare the two compounds ^[9]. Results are pending.

What indirect comparison shows: the Phase 2 retatrutide obesity trial produced a mean -24.2% body-weight change at 48 weeks ^[1]. Phase 3 tirzepatide data in comparable populations reached approximately -20-22% at 72 weeks. These numbers come from different trials, different populations, and different durations — they are not a valid head-to-head comparison. The NCT06662383 trial exists precisely because indirect comparisons are unreliable. The head-to-head result will be the correct answer to this question.

Phase 3 TRIUMPH program and outcomes trials

As of mid-2026, the TRIUMPH Phase 3 program covers obesity, type 2 diabetes, and dedicated outcomes arms. NCT06383390 is a trial evaluating once-weekly retatrutide on cardiovascular outcomes and kidney parameters ^[8]. The TRANSCEND-CKD trial addresses chronic kidney disease. NCT05929066 and NCT05931367 cover additional TRIUMPH arms.

A dedicated cardiovascular and kidney outcomes trial (NCT06383390) is ongoing — the long-term safety data the Phase 2 record cannot provide ^[8]. The cardiology review literature notes the theoretical potential for greater cardiovascular benefit from higher weight loss (retatrutide's ~24% versus comparators' ~20%), partly via pleiotropic effects on inflammation, endothelial function, and atherosclerosis — but cautions that outcome data for retatrutide specifically do not yet exist ^[11].

Sleep apnea and broader comorbidity signals

A 2025 paper in Diabetes, Obesity and Metabolism examined retatrutide-associated weight loss alongside improvements in obstructive sleep apnea severity and knee osteoarthritis-related pain endpoints ^[13]. A 2026 review in Lancet Diabetes & Endocrinology documented GLP-1-based and multiagonist therapies — including retatrutide — as showing beneficial effects across major obesity comorbidities, with weight-loss-independent effects emerging for obstructive sleep apnea and cardiometabolic conditions ^[12].

These signals are preliminary — trial data specifically designed for sleep apnea and osteoarthritis endpoints with retatrutide are not yet in the published record. They represent early mechanistic and secondary-endpoint observations in the broader incretin literature, not confirmed indications. A 2025 review in Peptides confirmed incretin therapies as a class show emerging benefit on fatty liver, inflammation, sleep apnea, bone, and cognition, with retatrutide named as an in-development triple agonist in that landscape ^[14].